Goldline Pharmaceutical Ltd
BSE: 544759
₹40.00
₹-0.97
(-2.37%)
As on 31-Aug-2026IST
Market cap
₹38 Cr
Revenue (TTM)
₹31 Cr
P/E Ratio
9.3
P/B Ratio
1.6
Div. Yield
0 %
Quality Score
5/10
Growth Score
7/10
Valuation Score
8/10
Momentum Score
UNRATED/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹4 Cr
-
ROE
39.4 %
-
ROCE
30.6 %
-
Industry P/E
15.36
-
EV/EBITDA
6.6
-
Debt to Equity
0.6
-
Book Value
₹18
-
EPS
₹6
-
Face value
10
-
Shares outstanding
9,600,000
Years Aggregate
CFO
₹--
EBITDA
₹--
Net Profit
₹--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Goldline Pharmaceutical
| -- | -0.3 | -17.4 | -- | -- | -- | -- |
|
BSE Healthcare
| 18.7 | 1.7 | 10.2 | 18.2 | 22.8 | 14.5 | 12.3 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Goldline Pharmaceutical
|
40.0 | 38.4 | 31.2 | 4.1 | -- | 39.4 | 9.3 | 1.6 |
| 145.8 | 183.3 | 38.2 | 9.8 | -- | 99.6 | 15.3 | -- | |
| 1,809.9 | 7,860.1 | 7,127.9 | 167.7 | 3.7 | 7.6 | 62.7 | 4.5 | |
| 26.5 | 32.2 | 12.6 | -1.8 | -77.2 | -1.6 | -- | 0.3 | |
| 20.6 | 29.2 | 49.7 | 4.1 | -- | 29.1 | 4.9 | 0.8 | |
| 31.5 | 19.8 | -3.0 | -0.1 | 17.3 | -0.7 | -- | 2.0 | |
| 36.3 | 19.9 | 562.1 | 1.2 | 0.4 | 9.8 | 16.1 | 10.5 | |
| 150.1 | 131.9 | 58.3 | 8.6 | -- | 37.9 | 10.1 | 1.9 | |
| 70.1 | 136.9 | 106.8 | 4.8 | -- | 14.9 | 27.4 | -- | |
| 0.2 | 29.7 | 365.5 | -17.0 | -2.0 | -14.3 | -- | 0.3 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Goldline Pharmaceutical
--
-
Incorporated
2004
-
Chairman
Amol Laxmikant Mujumdar
-
Managing Director
Amol Laxmikant Mujumdar
-
Headquarters
Nagpur, Maharashtra
-
Website
Looking for more details about Goldline Pharmaceutical Ltd’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Goldline Pharmaceutical
What is the current share price of Goldline Pharmaceutical Ltd Today?
The share price of Goldline Pharmaceutical Ltd is ₹40.00 (BSE) as of 31-Aug-2026 IST. Goldline Pharmaceutical Ltd has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Goldline Pharmaceutical Ltd?
The P/E ratio of Goldline Pharmaceutical Ltd is 9.33 times as on 31-Aug-2026, a 39 discount to its peers’ median range of 15.36 times.
The P/B ratio of Goldline Pharmaceutical Ltd is 1.60 times as on 31-Aug-2026, a 16 discount to its peers’ median range of 1.91 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
0.00 |
0.00 |
2025 |
0.00 |
0.00 |
2024 |
0.00 |
0.00 |
2023 |
0.00 |
0.00 |
2026 |
0.00 |
0.00 |
What is the 52 Week High and Low of Goldline Pharmaceutical Ltd?
The 52-week high and low of Goldline Pharmaceutical Ltd are Rs 60.00 and Rs 33.00 as of 31-Aug-2026.
What is the market cap of Goldline Pharmaceutical Ltd?
Goldline Pharmaceutical Ltd has a market capitalisation of ₹ 38 Cr as on 31-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Goldline Pharmaceutical Ltd?
Before investing in Goldline Pharmaceutical Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.